Finance

Lists
Why is ACRS up 7,47%?
Dive Deeper
ACRS:NASDAQ
Aclaris Therapeutics Inc
3,74 $
+7,47%
(+0,26) 1D
20 қаз., 11:15:36 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ACRS...
Open
3,41 $
High
3,80 $
Low
3,37 $
Mkt. cap
550,52 млн
Avg. vol.
3,72 млн
Volume
658,40 м.
52-wk high
6,60 $
52-wk low
2,03 $
EPS
-0,59 $
Beta
0,87
Shares outstanding
147,20 млн
No. of employees
71
Open
3,41 $
High
3,80 $
Low
3,37 $
Mkt. cap
550,52 млн
Avg. vol.
3,72 млн
Volume
658,40 м.
52-wk high
6,60 $
52-wk low
2,03 $
EPS
-0,59 $
Beta
0,87
Shares outstanding
147,20 млн
No. of employees
71
News stories
From web sources and news partners
About Aclaris Therapeutics Inc
CEO-
Employees71
Founded2012
Headquarters-
SectorPharmaceutical industry
Analyst ratings
Based on 5 analysts giving stock ratings to ACRS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ACRS in the last 3 months.
Highest
Current 3,74 $
16,00 $ (+327,81%)
Average
12,00 $ (+220,86%)
Lowest
10,00 $ (+167,38%)
Analyst
Recommendation
Action
Price target
Projected
Date
Biren Amin
Piper Sandler
Buy
Maintained
11,00 $
+194,1%
10/19/2026
Kate Dellorusso
LifeSci Capital
Buy
Maintained
13,00 $
+247,6%
10/01/2026
Edward Nash
Canaccord Genuity
Buy
Initiated
10,00 $
+167,4%
09/01/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
16,00 $
+327,8%
08/10/2026
Adam Vogel
Craig-Hallum
Buy
Maintained
10,00 $
+167,4%
08/06/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
12,00 $
+220,9%
05/11/2026
Martin Fan
Wedbush
Buy
Maintained
10,00 $
+167,4%
05/08/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
10,00 $
+167,4%
05/08/2026
Alex Thompson CFA
Stifel Nicolaus
Hold
Maintained
4,00 $
+7%
05/08/2026
Unknown Analyst
Goldman Sachs
Buy
Maintained
10,00 $
+167,4%
04/16/2026
Last report
2026 ж. 06 там.
Fiscal period
Q2 2026
-0,15 $ / -0,16 $
+6,25%beat
Revenue / Est. (USD)
1,63 млн / 1,54 млн
+6,11%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
3,30 млн
1,30 млн
2,00 млн
1,63 млн
Cost of goods sold
15,48 млн
18,05 млн
17,44 млн
19,52 млн
Cost of revenue
15,48 млн
18,05 млн
17,44 млн
19,52 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,87 млн
5,58 млн
6,74 млн
6,05 млн
Operating expense
4,87 млн
5,58 млн
6,74 млн
6,05 млн
Total operating expenses
20,35 млн
23,63 млн
24,19 млн
25,57 млн
Operating income
-17,05 млн
-22,33 млн
-22,19 млн
-23,94 млн
Other non operating income
716,00 м.
1,30 млн
854,00 м.
972,00 м.
EBT including unusual items
-14,61 млн
-19,80 млн
-19,82 млн
-21,50 млн
EBT excluding unusual items
-14,51 млн
-19,40 млн
-19,82 млн
-21,20 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14,61 млн
-19,80 млн
-19,82 млн
-21,50 млн
Net profit margin
-442,98%
-1 528,57%
-993,19%
-1 320,13%
Earnings per share
-0,12
-0,16
-0,15
-0,15
Interest and investment income
1,82 млн
1,63 млн
1,51 млн
1,76 млн
Interest expense
-
-
-
-
Net interest expenses
1,82 млн
1,63 млн
1,51 млн
1,76 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-17,04 млн
-22,32 млн
-22,19 млн
-23,94 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары